ArticlemBio2021
Effectors of the Stenotrophomonas maltophilia Type IV Secretion System Mediate Killing of Clinical Isolates of Pseudomonas aeruginosa.
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- A polyvalent phage shapes bacterial dynamics.Journal of virology · 2026Article
- Type VI-secretion system-mediated competition and virulence in clinical and environmentalMicrobiology spectrum · 2026Article
- Antimicrobial resistance mechanisms, treatment challenges, and emerging strategies inFrontiers in cellular and infection microbiology · 2026Review
- Diversity Among Clinical and Fresh Produce Isolates ofFoods (Basel, Switzerland) · 2025Article
- Stenotrophomonas maltophilia complex: A broadly distributed emerging pathogen.PLoS pathogens · 2025Article
- The dominant lineage of an emerging pathogen harbours contact-dependent inhibition systems.Microbial genomics · 2025Article
- The EDEN ISS mobile test facility microbiome changes by cleaning and continued use.Frontiers in microbiomes · 2025Article
- The type II secretion system as an underappreciated and understudied mediator of interbacterial antagonism.Infection and immunity · 2024Review
- Antibacterial potential ofmSphere · 2024Article
- Bactericidal effectors of themBio · 2024Article
- Conjugative type IV secretion systems enable bacterial antagonism that operates independently of plasmid transfer.Communications biology · 2024Article
- Antibiotic Resistance and Virulence Factors in Clinical Isolates ofInternational journal of microbiology · 2024Article
- Review
- The type VI secretion system of the emerging pathogenmSphere · 2023Article
- Mesenteric Adipose Tissue-Derived Klebsiella variicola Disrupts Intestinal Barrier and Promotes Colitis by Type VI Secretion System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- A guide toFrontiers in cellular and infection microbiology · 2023Review
- Antibacterial contact-dependent proteins secreted by Gram-negative cystic fibrosis respiratory pathogens.Trends in microbiology · 2022Review
- Molecular architecture of bacterial type IV secretion systems.PLoS pathogens · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Previously, we documented that Stenotrophomonas maltophilia encodes a type IV secretion system (T4SS) that allows the organism to kill, in contact-dependent fashion, heterologous bacteria, including wild-type Pseudomonas aeruginosa. Bioinformatic screens based largely on the presence of both a C-terminal consensus sequence and an adjacent gene encoding a cognate immunity protein identified 13 potential antibacterial effectors, most of which were highly conserved among sequenced strains of S. maltophilia. The immunity proteins of two of these proved especially capable of protecting P. aeruginosa and Escherichia coli against attack from the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.